MARKET

LGND

LGND

Ligand Pharma
NASDAQ
105.09
-0.54
-0.51%
After Hours: 103.80 -1.29 -1.23% 19:20 05/14 EDT
OPEN
107.51
PREV CLOSE
105.63
HIGH
108.45
LOW
104.50
VOLUME
164.80K
TURNOVER
--
52 WEEK HIGH
129.90
52 WEEK LOW
77.43
MARKET CAP
2.03B
P/E (TTM)
-14.7617
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LGND last week (0505-0509)?
Weekly Report · 2d ago
RBC Capital Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks · 2d ago
Ligand Pharmaceuticals Price Target Raised to $145.00/Share From $142.00 by Oppenheimer
Dow Jones · 5d ago
Ligand Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 5d ago
Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $145
Benzinga · 5d ago
Craig-Hallum Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks · 5d ago
Ligand price target raised to $145 from $142 at Oppenheimer
TipRanks · 5d ago
LIGAND PHARMACEUTICALS, INC. <LGND.O>: OPPENHEIMER RAISES TARGET PRICE TO $145 FROM $142
Reuters · 5d ago
More
About LGND
More
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Recently
Symbol
Price
%Change

Webull offers Ligand Pharmaceuticals Inc stock information, including NASDAQ: LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.